...according to a study published in the journal 'Neurology'...."This randomised, controlled trial in 66 patients showed the drug was significantly superior to placebo. Sixty-five per cent of those taking part needed support to walk or were wheelchair users. They suffered from moderate to severe central neuropathic pain which had not been alleviated by currently available medications. Patients continued to take their existing medication throughout the trial. Sativex was administered as an oral spray, allowing flexible dosing suited to the variable nature of MS.

Dr Carolyn Young, the principal investigator and consultant neurologist at the Walton Centre for Neurology and Neurosurgery in Liverpool, said, "Central neuropathic pain occurs frequently in people with MS. It can be tremendously debilitating and unresponsive to existing therapies. Our findings demonstrate that Sativex was effective in reducing both central pain in MS and pain-related sleep disturbance in a population with moderate to severe central pain inadequately relieved by existing medication."Multiple Sclerosis Society Website